SAN DIEGO – The VARSITY study results showed that clinical and endoscopic outcomes of Entyvio treatment were superior to those of Humira in moderately to severely active ulcerative colitis at 1 year, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Vedolizumab ...

Credit: Shutterstock. Vedolizumab (Entyvio; Takeda), an integrin receptor antagonist, was found to be superior to adalimumab (Humira; AbbVie), a tumor necrosis factor-alpha (TNFα) antagonist, in ...

- ENTYVIO ® superior to Humira ® in achieving clinical remission and mucosal healing at week 52 in patients with moderately to severely active ulcerative colitis OAKVILLE, ON, March 11, 2019 /CNW/ - ...

The FDA announced a new contender in the ulcerative colitis and Crohn’s disease treatment space: Takeda, which scored approval of its infusion drug Entyvio for adults with moderate-to-severe forms of ...

Entyvio conferred superior clinical remission and mucosal healing compared with Humira among patients with moderately to severely active ulcerative colitis, according to results of a phase 3b ...

EXTON, Pa., Sept. 24, 2020 /PRNewswire/ -- The 2020 audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (US) service focuses on a critical facet of overall ...

Takeda’s Entyvio has beaten AbbVie’s Humira on achieving clinical remission in patients with ulcerative colitis, in the first trial to directly compare the efficacy and safety of two commonly used ...

Inflammatory bowel disease is a chronic condition that can cause diarrhea, pain, bleeding, anemia, intestinal blockage, and other serious problems. The two most common types of IBD are Crohn's disease ...

Takeda is finally over the hump with its inflammatory bowel disease drug Entyvio after safety questions threatened its approval. And while the drug will take a backseat to a few of the market's ...